Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). In trial results for this indication announced late last year the drug met all of its primary and secondary endpoints, significantly reducing nasal polyp size, nasal congestion severity, and the need for systemic corticosteroids and/or surgery. Now new results announced at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Francisco show that the drug improved nasal polyp size, nasal congestion severity, chronic sinus disease, sense of smell and co-morbid asthma outcomes. Dupixent also reduced the need for systemic corticosteroid use and the need for nasal/sinus surgery. CRSwNP is a chronic disease of the upper airway predominantly driven by Type 2 inflammation and characterized by polyps that obstruct the sinuses and nasal passages.